Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months.

Much of this was due to a very well-received quarterly earnings report.

Bausch + Lomb has added four new directors at the request of Bausch Health, including its parent's chief executive.

Personalized AI health app VerilyMe is visualizing expanded eye health education in a new partnership with eye health-focused drugmaker Bausch + Lomb.  | The partnership marks Basuch + Lomb's foray ...

What Bausch + Lomb’s latest quarter tells you Bausch + Lomb (NYSE:BLCO) drew fresh attention after reporting second quarter ...

"Leverage in the P&L, margin expansion, broad-based revenue growth, improved cash flow generation" continued in Q2, with CEO Brenton L. Saunders pointing to "8% constant currency revenue growth" and ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...

AI is being talked about as though business has never encountered a technological shift before. And just like the other times ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has entered ...

Bausch & Lomb enhanced its longstanding partnership with Rochester Institute of Technology today by announcing that the Bausch & Lomb Foundation is committing $2.5 million dollars to fund the Bausch & ...

LAVAL, QB, June 23, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the U.S. launch of ...